BR112018008081A2 - métodos para a cultura de células e kits e aparelho para os mesmos - Google Patents

métodos para a cultura de células e kits e aparelho para os mesmos

Info

Publication number
BR112018008081A2
BR112018008081A2 BR112018008081A BR112018008081A BR112018008081A2 BR 112018008081 A2 BR112018008081 A2 BR 112018008081A2 BR 112018008081 A BR112018008081 A BR 112018008081A BR 112018008081 A BR112018008081 A BR 112018008081A BR 112018008081 A2 BR112018008081 A2 BR 112018008081A2
Authority
BR
Brazil
Prior art keywords
agents
methods
proliferation
expansion
stimulation
Prior art date
Application number
BR112018008081A
Other languages
English (en)
Inventor
Stemberger Christian
Bashour Keenan
Germeroth Lothar
GRÄF Patricia
Original Assignee
Juno Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Gmbh filed Critical Juno Therapeutics Gmbh
Publication of BR112018008081A2 publication Critical patent/BR112018008081A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/20—Small organic molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

fornecidos aqui são os métodos que relatam, em alguns aspectos, à incubação ou cultura, tal como para induzir a estimulação da expansão (proliferação), ativação, coestimulação e / ou sobrevivência, de uma composição de células, tal como uma população de linfócitos. em alguns aspectos, fornecidos são métodos e reagentes para a estimulação, por exemplo, de expansão (proliferação), sobrevivência ou persistência, ativação, coestimulação, ou outro efeito, de populações de célula que envolvem a ligação de agentes a uma molécula sobre a superfície das células, desse modo fornecendo um ou mais sinais às células. em alguns casos, os reagentes são reagentes contendo uma pluralidade de sítios de ligação para agentes, tais como reagentes de multimerização, e desse modo a um ou mais agentes são multimerizados ligando-se reversivelmente ao reagente, por exemplo, desse modo criando um reagente estimulatório (agente multimerizado), tendo agentes estimulatórios neste. em alguns aspectos, o agente multimerizado pode fornecer para expansão ou proliferação ou outra estimulação de uma população de células, e em seguida tais agentes estimulatórios podem ser removidos por ruptura da ligação reversível. da mesma forma fornecidos são as composições, aparelhos e métodos de uso dos mesmos.
BR112018008081A 2015-10-22 2016-10-20 métodos para a cultura de células e kits e aparelho para os mesmos BR112018008081A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562245252P 2015-10-22 2015-10-22
US201562245261P 2015-10-22 2015-10-22
PCT/IB2016/001618 WO2017068421A1 (en) 2015-10-22 2016-10-20 Methods for culturing cells and kits and apparatus for same

Publications (1)

Publication Number Publication Date
BR112018008081A2 true BR112018008081A2 (pt) 2018-11-13

Family

ID=57394616

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008081A BR112018008081A2 (pt) 2015-10-22 2016-10-20 métodos para a cultura de células e kits e aparelho para os mesmos

Country Status (17)

Country Link
US (2) US11466253B2 (pt)
EP (1) EP3365434A1 (pt)
JP (3) JP6895959B2 (pt)
KR (1) KR20180100110A (pt)
CN (2) CN108431210B (pt)
AU (1) AU2016341529B2 (pt)
BR (1) BR112018008081A2 (pt)
CA (1) CA3002745A1 (pt)
HK (1) HK1258931A1 (pt)
IL (2) IL307934A (pt)
MA (1) MA45488A (pt)
MX (3) MX2018004874A (pt)
NZ (1) NZ741878A (pt)
PH (1) PH12018500860A1 (pt)
RU (1) RU2761557C2 (pt)
SG (1) SG11201803330WA (pt)
WO (1) WO2017068421A1 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047482A2 (en) 2003-11-12 2005-05-26 Xiao Xu Real time electronic cell sensing systems and applications for cell-based assays
US8263375B2 (en) 2002-12-20 2012-09-11 Acea Biosciences Dynamic monitoring of activation of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology
US11346797B2 (en) 2002-12-20 2022-05-31 Agilent Technologies, Inc. System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties
US10215748B2 (en) 2002-12-20 2019-02-26 Acea Biosciences, Inc. Using impedance-based cell response profiling to identify putative inhibitors for oncogene addicted targets or pathways
US10551371B2 (en) 2003-11-10 2020-02-04 Acea Biosciences, Inc. System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function
US10539523B2 (en) 2002-12-20 2020-01-21 Acea Biosciences, Inc. System and method for monitoring cardiomyocyte beating, viability, morphology, and electrophysiological properties
WO2009137440A1 (en) 2008-05-05 2009-11-12 Acea Biosciences, Inc. Label-free monitoring of excitation-contraction coupling and excitable cells using impedance based systems with millisecond time resolution
JP6362543B2 (ja) 2012-02-23 2018-07-25 ジュノ セラピューティクス ゲーエムベーハー 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離
MY184699A (en) 2014-04-16 2021-04-18 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
MA45426A (fr) 2015-10-22 2019-05-01 Juno Therapeutics Gmbh Procédés, kits, agents et appareils de transduction
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
BR112019009925A2 (pt) 2016-11-17 2019-10-08 Iovance Biotherapeutics Inc método para preparar linfócitos infiltrantes de tumor remanescente para terapia de células t adotivas, e, método de tratamento de um câncer .
EP3565586A1 (en) 2017-01-06 2019-11-13 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
EP3589299A4 (en) 2017-03-03 2021-01-13 ACEA Biosciences, Inc. METHODS AND SYSTEMS FOR FUNCTIONAL MATURATION OF CARDIOMYOCYTES FROM IPSC AND ESC
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
NZ758485A (en) 2017-04-27 2024-02-23 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
CN110770348B (zh) * 2017-06-01 2023-12-15 浙江煦顼技术有限公司 嵌合抗原受体细胞的制备及其用途
US11235004B2 (en) 2017-06-30 2022-02-01 Innovative Cellular Therapeutics Holdings, Ltd. Lymphocyte cell lines and uses thereof
US20210364494A1 (en) * 2017-08-01 2021-11-25 Acea Biosciences, Inc. Cell-substrate impedance monitoring of cancer cells of different lineage, origin, or stage
US11851678B2 (en) 2017-08-09 2023-12-26 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
JP7438988B2 (ja) 2018-06-13 2024-02-27 ノバルティス アーゲー Ｂｃｍａキメラ抗原受容体及びその使用
WO2020033312A1 (en) * 2018-08-06 2020-02-13 Medikine, Inc. Il-2 receptor binding compounds
KR20210057730A (ko) * 2018-08-09 2021-05-21 주노 쎄러퓨티크스 인코퍼레이티드 조작 세포 및 이의 조성물 생성 방법
CA3110089A1 (en) * 2018-08-28 2020-03-05 Fred Hutchinson Cancer Research Center Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
JP2021534783A (ja) * 2018-08-31 2021-12-16 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
SG11202104355SA (en) * 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
AU2019375997A1 (en) 2018-11-08 2021-06-03 Neximmune, Inc. T cell compositions with improved phenotypic properties
WO2020146434A2 (en) * 2019-01-07 2020-07-16 Children's National Medical Center Ex vivo activated t-lymphocytic compositions and methods of using the same
KR20200132147A (ko) * 2019-05-15 2020-11-25 의료법인 성광의료재단 자연 살해 세포의 배양용 조성물 및 이를 이용한 방법
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
JP2023500318A (ja) 2019-10-30 2023-01-05 ジュノ セラピューティクス ゲーエムベーハー 細胞選択および／または細胞刺激デバイスならびに使用方法
WO2021092075A1 (en) 2019-11-05 2021-05-14 Medikine Inc. IL-2RβγC BINDING COMPOUNDS
AU2020389422A1 (en) * 2019-11-20 2022-06-02 Gi Cell, Inc. Medium composition for culturing T cells and method for culturing T cells using same
CN117660331A (zh) * 2019-11-20 2024-03-08 吉爱希公司 用于培养自然杀手细胞的组合物及使用其来生产自然杀手细胞的方法
KR20220104217A (ko) 2019-11-26 2022-07-26 노파르티스 아게 Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
KR102400253B1 (ko) 2019-11-27 2022-05-23 ㈜지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 면역관문 억제제를 포함하는 암 치료용 약학 조성물
CN115003818A (zh) * 2020-01-22 2022-09-02 科济生物医药（上海）有限公司 病毒载体转导细胞的方法
WO2021158623A1 (en) 2020-02-03 2021-08-12 Medikine, Inc. IL-7Rαγc BINDING COMPOUNDS
EP4107187A1 (en) 2020-02-21 2022-12-28 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
US20230398148A1 (en) 2020-11-04 2023-12-14 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
CN113125733A (zh) * 2021-04-16 2021-07-16 浙江普罗亭健康科技有限公司 一种用于监测人体免疫状态的42抗体试剂盒及应用
CN113125718A (zh) * 2021-04-16 2021-07-16 浙江普罗亭健康科技有限公司 一种用于监测人体免疫状态的45抗体试剂盒及应用
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
WO2022254337A1 (en) 2021-06-01 2022-12-08 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023213969A1 (en) * 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
EP0198015B2 (en) 1984-10-02 1995-07-19 Biogen, Inc. Production of streptavidin-like polypeptides
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (pt) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
JPH08511166A (ja) 1993-06-04 1996-11-26 アメリカ合衆国 Ｔ細胞の増殖を選択的に刺激する方法
EP0638644A1 (en) 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Receptors of interleukin-12 and antibodies
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5853721A (en) 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
JPH11501008A (ja) 1995-02-09 1999-01-26 ユニバーシティ オブ ワシントン 改変−アフィニティーストレプトアビジン
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US6022951A (en) 1995-04-11 2000-02-08 Univ Boston Streptavidin mutants
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US6140064A (en) 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
CA2283716A1 (en) 1997-03-14 1998-09-17 Gabriel O. Reznik Multiflavor streptavidin
US5985658A (en) 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
US6153441A (en) 1998-02-17 2000-11-28 Smithkline Beecham Corporation Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
DK1616579T3 (da) 1998-05-23 2009-09-14 Univ Leiden Medical Ct CD40 bindende molekyler og CTL peptider til behandling af tumorer
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
CN100402642C (zh) 1999-02-04 2008-07-16 技术研究及发展基金有限公司 维持和扩增造血干细胞和/或祖细胞的方法和仪器
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
JP2003524644A (ja) 2000-02-01 2003-08-19 タノックス インコーポレイテッド Ｃｄ４０−結合性ａｐｃ−活性化分子
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
DE60138222D1 (de) 2000-09-14 2009-05-14 Beth Israel Hospital Modulierung von il-2 und il-15 vermittelten t zellantworten
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
CN101508734A (zh) 2001-04-27 2009-08-19 协和发酵麒麟株式会社 抗cd40单克隆抗体
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
CA2460321A1 (en) 2001-09-20 2003-03-27 Schering Corporation Chemokines as adjuvants of immune response
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
DE50312184D1 (de) 2002-03-01 2010-01-14 Volker A Erdmann Streptavidin-bindungspeptid
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7754155B2 (en) 2002-03-15 2010-07-13 Ross Amelia A Devices and methods for isolating target cells
US20050271653A1 (en) 2002-04-23 2005-12-08 Meir Strahilevitz Methods and devices for targeting a site in a mammal and for removing species from a mammal
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2007001459A2 (en) 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
FR2841905B1 (fr) 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
CN102061288A (zh) 2002-07-17 2011-05-18 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20060159655A1 (en) 2003-03-21 2006-07-20 Wyeth Treating immunological disorders using agonists of interleukin-21 / interleukin-21 receptor
TW200502391A (en) 2003-05-08 2005-01-16 Xcyte Therapies Inc Generation and isolation of antigen-specific t cells
US7943393B2 (en) 2003-07-14 2011-05-17 Phynexus, Inc. Method and device for extracting an analyte
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
US20080050795A1 (en) 2003-11-20 2008-02-28 Biosensor Applications Sweden Ab Mixture Of At Least Two Different Antibodies Specific For Predetermined Antigens And Use Of The Mixture
WO2005059106A2 (en) 2003-12-10 2005-06-30 Medarex, Inc. Interferon alpha antibodies and their uses
SE0400181D0 (sv) 2004-01-29 2004-01-29 Gyros Ab Segmented porous and preloaded microscale devices
CA2555714C (en) 2004-02-26 2013-12-03 Immunovative Therapies, Ltd. Methods for preparing t-cells for cell therapy
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
DE602005013957D1 (de) 2004-06-03 2009-05-28 Meso Scale Technologies Llc Verfahren zur durchführung von vollbluttests
RU2600884C2 (ru) 2004-06-21 2016-10-27 Е. Р. Сквибб энд Сонз, Эл,Эл.Си Антитела рецептора 1 интерферона альфа и их применение
WO2006007486A2 (en) 2004-07-01 2006-01-19 New York University COMPOSITIONS AND METHODS FOR MODULATION OF RORϜt
EP1773394A2 (en) 2004-08-05 2007-04-18 Wyeth a Corporation of the State of Delaware Antagonizing interleukin-21 receptor activity
WO2006044650A2 (en) 2004-10-15 2006-04-27 Genencor International, Inc. Competitive differential screening
CA2586615C (en) 2004-11-12 2017-06-27 Genentech, Inc. Pro87299 (btla), and variants thereof, for treating immune related disorders
WO2006058226A2 (en) 2004-11-24 2006-06-01 The Trustees Of Boston University Modified dimeric streptavidins and uses thereof
US20060252087A1 (en) 2005-01-18 2006-11-09 Biocept, Inc. Recovery of rare cells using a microchannel apparatus with patterned posts
US7553932B1 (en) 2005-04-25 2009-06-30 La Jolla Institute For Allergy And Immunology Methods of treating viral infection with IL-10 receptor antagonists
AU2006298767B2 (en) 2005-09-28 2013-01-10 Cytos Biotechnology Ag Interleukin-1 conjugates and uses thereof
KR101408565B1 (ko) * 2005-09-30 2014-06-17 다카라 바이오 가부시키가이샤 Ｔ 세포 집단의 제조 방법
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US7704708B2 (en) 2006-02-13 2010-04-27 Uti Limited Partnership Monomeric streptavidin muteins
US7855057B2 (en) 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US8557955B2 (en) 2006-10-17 2013-10-15 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
CN101568834A (zh) 2006-11-02 2009-10-28 协和梅迪克斯株式会社 待测组分的免疫测定方法
EP2518193A3 (en) 2006-11-15 2013-01-23 Invitrogen Dynal AS Methods for reversibly binding a biotin compound to a support
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
DK2101877T3 (da) 2006-12-28 2013-09-23 Deutsches Krebsforsch Neutralisering af virkningen af CD95 til blokering af invasion af glioblastomceller in vivo
CN101226118B (zh) 2007-01-19 2010-06-16 中国医学科学院肿瘤研究所 一种兼容免疫荧光分析的细胞化学染色方法及其用途
KR20080076622A (ko) 2007-02-16 2008-08-20 포항공과대학교 산학협력단 올리고머화된 단백질 전달체와 이를 이용한 세포내바이러스 벡터 전달 방법
US8709980B2 (en) 2007-03-26 2014-04-29 Celexion, Llc Cell surface display, screening and production of proteins of interest
NO2856876T3 (pt) 2007-03-30 2018-06-30
AU2008247382B2 (en) 2007-05-07 2014-06-05 Medimmune, Llc Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8735330B2 (en) 2007-08-20 2014-05-27 Nextera As pVII phage display
EP2227334B1 (en) 2007-12-07 2011-10-12 Miltenyi Biotec GmbH A centrifuge for separating a sample into at least two components
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
AU2009205956B2 (en) 2008-01-18 2015-07-02 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
EP3363893B1 (en) 2008-01-29 2021-06-30 Fred Hutchinson Cancer Research Center Identification of cd8+ t cells that are cd161hi and/or il18ralphahi and have rapid drug efflux capacity
WO2009095447A1 (en) 2008-01-30 2009-08-06 Pieris Ag Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same
WO2009145831A1 (en) 2008-04-02 2009-12-03 Geisinger Clinic Treatment of the idiopathic nephrotic syndrome spectrum diseases using basiliximab
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
US9023999B2 (en) 2008-06-30 2015-05-05 Kyowa Hakko Kirin Co., Ltd Anti-CD27 antibody
US8775327B2 (en) 2008-07-03 2014-07-08 Oracle International Corporation Combined directory of personal and enterprise application system data
US20100055098A1 (en) 2008-08-28 2010-03-04 Facet Biotech Corporation Method for treating multiple sclerosis patients with anti-il2r antibodies
CN101446576B (zh) 2008-12-29 2011-06-22 江苏省苏微微生物研究有限公司 一种微囊藻毒素-lr单抗免疫亲和柱的制备和使用方法
WO2010080032A2 (en) 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
CA2758542A1 (en) 2009-04-17 2010-10-21 New York University Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof
WO2010126890A1 (en) 2009-04-27 2010-11-04 Facet Biotech Corporation Methods for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
EP2473851A1 (en) 2009-08-31 2012-07-11 Abbott Biotherapeutics Corp. Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
WO2011053971A2 (en) 2009-11-02 2011-05-05 Fina Biosolutions, Llc Method for enhancing the sensitivity of antibody based assays
US20120321665A1 (en) 2009-12-14 2012-12-20 Benaroya Research Institute At Virginia Mason Compositions and methods for treating airway inflammatory diseases
EP2363501A1 (en) 2010-03-02 2011-09-07 Universitätsklinikum Hamburg-Eppendorf Method for isolating target cells
CA2796571C (en) 2010-04-13 2019-10-29 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
EP2601521B1 (en) 2010-08-06 2018-05-02 Ludwig-Maximilians-Universität München Identification of t cell target antigens
WO2012058627A2 (en) 2010-10-29 2012-05-03 Miqin Zhang Pre-targeted nanoparticle system and method for labeling biological particles
PL3214091T3 (pl) 2010-12-09 2019-03-29 The Trustees Of The University Of Pennsylvania Zastosowanie komórek T modyfikowanych chimerycznymi receptorami antygenowymi do leczenia nowotworów
CA2824278C (en) 2010-12-20 2022-09-20 The Rockefeller University Modulating agonistic tnfr antibodies
NZ743310A (en) 2011-03-23 2022-11-25 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
EP3418295B1 (en) * 2011-07-18 2020-09-02 IBA GmbH Method of reversibly staining a target cell
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
BR112014011417B1 (pt) 2011-11-11 2021-10-13 Fred Hutchinson Cancer Research Center Polipeptídeo isolado capaz de elicitar uma resposta de célula t antígeno-específica para ciclina a1 humana, composição imunogênica compreendendo o referido polipeptídeo, bem como método para preparar células apresentadoras de antígeno, antígeno-pulsadas,e uso destas para superexpressão de ccna1
AU2013221672B2 (en) 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
JP6362543B2 (ja) 2012-02-23 2018-07-25 ジュノ セラピューティクス ゲーエムベーハー 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離
CA2867299C (en) 2012-03-15 2019-08-27 John Chen Human anti-cd27 antibodies, methods, and uses
JP6251734B2 (ja) 2012-05-03 2017-12-27 フレッド ハッチンソン キャンサー リサーチ センター 親和性増強型ｔ細胞受容体およびその作製方法
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
PT2884999T (pt) 2012-08-20 2021-01-05 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapêutica celular
WO2014039044A1 (en) 2012-09-06 2014-03-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t memory stem cell populations
EP2711418B1 (en) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
WO2014055668A1 (en) 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
EP2920204B1 (en) 2012-11-16 2019-09-18 IBA GmbH Streptavidin muteins and methods of using them
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
EP3027210A1 (en) 2013-08-02 2016-06-08 Aduro Biotech Holdings, Europe B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
KR102483822B1 (ko) 2013-12-20 2023-01-03 프레드 허친슨 캔서 센터 태그된 키메라 이펙터 분자 및 그의 리셉터
HUE046767T2 (hu) 2014-03-31 2020-03-30 Hoffmann La Roche Anti-OX40 antitestek és alkalmazási eljárások
MX2016012779A (es) 2014-03-31 2017-04-27 Genentech Inc Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
MY184699A (en) 2014-04-16 2021-04-18 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
IL292038A (en) 2014-04-23 2022-06-01 Juno Therapeutics Inc Methods for enriching and producing immune cell populations for stress treatment
US10131876B2 (en) 2014-04-24 2018-11-20 Miltenyi Biotec Gmbh Method for automated generation of genetically modified T cells
US11150239B2 (en) 2014-04-30 2021-10-19 Iba Lifesciences Gmbh Method of isolating a target cell
EP2955196A1 (en) 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
EP3161003A2 (en) 2014-06-27 2017-05-03 Apogenix GmbH Combination of cd95/cd95l inhibition and cancer immunotherapy
AU2015332151A1 (en) 2014-10-18 2017-04-27 Pfizer Inc. Anti-IL-7R antibody compositions
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
MA45426A (fr) 2015-10-22 2019-05-01 Juno Therapeutics Gmbh Procédés, kits, agents et appareils de transduction
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
AU2016363025B2 (en) 2015-12-03 2021-04-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
MA47325A (fr) 2017-01-20 2019-11-27 Juno Therapeutics Gmbh Conjugués de surface cellulaire et compositions cellulaires et méthodes associées
NZ758485A (en) 2017-04-27 2024-02-23 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
KR20210057730A (ko) 2018-08-09 2021-05-21 주노 쎄러퓨티크스 인코퍼레이티드 조작 세포 및 이의 조성물 생성 방법
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same

Also Published As

Publication number Publication date
US20230295567A1 (en) 2023-09-21
HK1258931A1 (zh) 2019-11-22
JP2023138707A (ja) 2023-10-02
IL307934A (en) 2023-12-01
MX2022012147A (es) 2023-03-01
NZ741878A (en) 2024-03-22
US20190136186A1 (en) 2019-05-09
WO2017068421A1 (en) 2017-04-27
CN117106716A (zh) 2023-11-24
AU2016341529B2 (en) 2023-03-30
RU2018118575A (ru) 2019-11-27
IL258844B2 (en) 2024-03-01
PH12018500860A1 (en) 2018-11-05
CN108431210A (zh) 2018-08-21
RU2761557C2 (ru) 2021-12-09
RU2018118575A3 (pt) 2020-07-28
JP7390334B2 (ja) 2023-12-01
KR20180100110A (ko) 2018-09-07
IL258844A (en) 2018-06-28
JP2018531035A (ja) 2018-10-25
MX2018004874A (es) 2018-12-12
CN108431210B (zh) 2023-05-23
CA3002745A1 (en) 2017-04-27
AU2016341529A1 (en) 2018-05-10
US11466253B2 (en) 2022-10-11
MA45488A (fr) 2018-08-29
MX2022012148A (es) 2023-03-01
IL258844B1 (en) 2023-11-01
JP6895959B2 (ja) 2021-06-30
EP3365434A1 (en) 2018-08-29
SG11201803330WA (en) 2018-05-30
JP2021137025A (ja) 2021-09-16

Similar Documents

Publication Publication Date Title
BR112018008081A2 (pt) métodos para a cultura de células e kits e aparelho para os mesmos
BR112018008061A2 (pt) métodos para a cultura de células e kits e aparelhos para os mesmos
BR112018008111A2 (pt) métodos, kits, agentes e aparelhos para transdução
BR112015001620A2 (pt) composição de meio de cultura, e método para cultivo de célula ou tecido usando-se dita composição
BR112015027996A8 (pt) Organoides compreendendo células renais isoladas e suas utilizações
GB2525104A (en) Massively parallel single cell analysis
BR112016024072A2 (pt) métodos, kits e aparelho para ampliar uma população de células
BR112017018941B8 (pt) Molécula de ligação a cd20, seu uso, composição e método in vitro para direcionar a morte mediada por complemento de uma célula que expressa cd20
BRPI0921687A8 (pt) Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
BR112015022322A2 (pt) sistemas e métodos para detecção de células com o uso de partículas de transdução projetadas
BR112017006469A2 (pt) composições e métodos para inibição de expressão do gene hao1 (hidroxiácido oxidase 1 (glicolato oxidase))
BR112017014902A2 (pt) processos e sistemas para a preparação de bibliotecas de sequenciamento de ácido nucleico e bibliotecas preparadas usando os mesmos
BR112015016005A2 (pt) preparação de amostra em um suporte sólido
BRPI0814343A2 (pt) Materiais e métodos para a seleção da sexagem do esperma
BR112013022832A2 (pt) linhagens de células de baixo teor de fucose e usos das mesmas
BR112014003139A2 (pt) musgo de turfa umectável resistente à lixiviação, método de preparação, e método de uso
WO2017087759A8 (en) Cartridge-based system for long term culture of cell clusters
BR112018001686A2 (pt) conjunto de sonda para analisar uma amostra de dna e método para usar o mesmo
BR112017015203A2 (pt) anticorpos de penetração celular
BR112015019865A2 (pt) composições de copolímero de alfa-olefina de alta viscosidade e métodos de preparação e uso das mesmas
BR112018076528A2 (pt) composições e métodos para diagnosticar cânceres de pulmão usando perfis de expressão gênica
BR112019000323A2 (pt) arcabouços de biomatriz para uso no diagnóstico e modelagem de câncer
BR112016029835A2 (pt) moléculas com certas utilidades pesticidas e intermediários, composições e processos relacionados aos mesmos
BR112016028537A2 (pt) expansão e enxerto de células-tronco utilizando agonistas de notch 1 e/ou de notch 2
BR112022016490A2 (pt) Métodos para enriquecimento ex vivo e expansão de células t reativas tumorais e composições relacionadas das mesmas

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: JUNO THERAPEUTICS GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]